The usefulness of [ 68 Ga]Ga-DOTA-JR11 PET/CT in patients with meningioma: comparison with MRI

Purpose Clinical studies of PET imaging using SSTR2 agonists have demonstrated high accuracy and correlation with SSTR2 expression in meningiomas. However, the usefulness of the SSTR2 antagonist with [ (68) Ga]Ga-DOTA-JR11 is uncertain. To evaluate the diagnostic performance of [(68) Ga]Ga-DOTA-JR11 PET/CT and to clarify tumor characteristics in patients with suspected meningiomas. Materials and methods Patients with suspected de novo or recurrent meningioma in complex locations or atypical images were enrolled from August 2021 to October 2022 in prospective study. All patients underwent contrast-enhanced MRI (CE-MRI), [(68) Ga]Ga-DOTA-JR11 PET/CT, and histopathological evaluation. Tumor uptake of [(68) Ga]Ga-DOTAJR11 was measured by SUVmax and tumor-endocranium ratio ( TBR). Diagnostic performance was compared between PET and MRI. Results Of 36 (50.0 +/- 13.0 years of age, 20 women) patients, 32 were histopathologically confirmed meningiomas and four with other tumors. [(68) Ga]Ga-DOTA-JR11 uptake was significantly higher in meningioma patients than in those with other tumors (SUVmax: 13.6 +/- 7.7 vs. 5.2 +/- 3.0, P < 0.001; TBR: 64.2 +/- 27.7 vs. 25.0 +/- 18.9, P = 0.001). [(68) Ga]Ga-DOTAJR11 PET/CT detected 31 meningiomas, while CE-MRI detected 17 meningiomas of 25 initial diagnosis and 11 recurrent tumors; [(68) Ga]Ga-DOTA-JR11 PET had an incremental diagnostic value of 24% (6/25) over MRI in the group of initial diagnosis. There was no statistically significant difference in diagnostic efficacy between PET and MRI (P = 0.45) for all 36 patients. In skull base meningiomas, PET provided a more definitive diagnosis of pituitary involvement (in 12, not in12), compared to MRI (in eight, possible in six, possible not in six, not in four). PET revealed bone involvement in all 14 patients proven by pathology, while MRI identified only 11. Conclusions [(68) Ga] Ga- DOTA-JR11 PET/CT provided high image quality and presented an ideal diagnostic performance in detecting meningioma and evaluating the involvement of the pituitary and bone. The study provides valuable evidence for the use of [(68) Ga]Ga-DOTA- JR11 PET/CT as a complementary imaging modality to CE- MRI in the evaluation of meningiomas.

Automated summary

This study evaluated the diagnostic performance of [(68) Ga]Ga-DOTA-JR11 PET/CT in detecting meningiomas and found it to be superior in tumor uptake compared to other tumors. The study also found that [(68) Ga]Ga-DOTA-JR11 PET/CT had a higher diagnostic value in initial diagnosis. In specific cases, PET provided more accurate determination of pituitary involvement and bone involvement compared to MRI.